Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Advanced Cancer 1

Interventions

Nivolumab 6Ipilimumab 46-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2tilsotolimod 1relatlimab 1mirdametinib 1linrodostat 1gedatolisib 1figitumumab 1Valganciclovir 1Tablets 1Surveys and Questionnaires 1Sunitinib 1Paclitaxel 1LY2584702 1Irinotecan 1EC145 1Dasatinib 1Chlorogenic Acid 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Cancer × Tablets × Clear all
NCT06302140 2025-01-20

A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers

Viracta Therapeutics, Inc.

Phase 1 Terminated
8 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡